Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Health and Me on MSN6h
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
1d
LGBTQ Nation on MSNOnce-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results